Drug Insights

Anaprazole Sodium——Next Generation Proton Pump Inhibitors

26 July 2023
2 min read

Anaprazole Sodium is a small molecule proton pump inhibitor (PPI) developed by Beijing Sihuan Pharmaceutical Co. Ltd., approved by NMPA on June 21, 2023, for the treatment of duodenal ulcers.

Anaprazole Sodium is PPI, a benzimidazole compound, which can inhibit gastric acid secretion by inhibiting H+- K+- ATP enzymatic activity of parietal cell and reducing proton transport capacity. 

Efficacy

In a multicenter, randomized, double blind, double simulated, and positive drug parallel controlled phase III study (NCT04215653), patients with duodenal ulcers were randomly treated with Anaprazole Sodium+placebo or Rabeprazole+placebo in a 1:1 ratio (once daily for 4 weeks). The primary efficacy endpoint was the 4-week ulcer healing rate evaluated through blind independent review. The secondary endpoint is the proportion of patients with overall and individual improvement in duodenal ulcer symptoms at 4 weeks. This study included 448 patients (Anaprazole Sodium, n=225; Rabeprazole, n=223). The 4-week healing rates of Anaprazole Sodium and Rabeprazole were 90.9% and 93.7%, respectively, indicating that Anaprazole Sodium has no adverse effect on Rabeprazole. The overall symptom improvement rates of duodenal ulcers were 90.9% and 92.5%, respectively, and the improvement rates of individual symptoms in each group were similar. There was no significant difference in the cure rate between the two groups. 

Safety

The incidence of sudden adverse events in the treatment of Anaprazole Sodium (72/220, 32.7%) and Anaprazole Sodium (84/219, 38.4%) is similar. 

Competitive Landscape

According to Synapse, there are 82 PPI drugs, of which 36 have been approved, and the competitive environment is not severe. For more information, please click on the image link below. 

图表

描述已自动生成

Targeting the Siglec-9 Immune Checkpoint: A New Approach to Enhance Immunotherapy
Advanced Tech.
5 min read
Targeting the Siglec-9 Immune Checkpoint: A New Approach to Enhance Immunotherapy
25 July 2023
The studies discussed here provide a foundation for the development of novel approaches to improve the efficacy of cancer immunotherapy.
Read →
Delandistrogene moxeparvovec - The first DMD Gene Therapy
Drug Insights
3 min read
Delandistrogene moxeparvovec - The first DMD Gene Therapy
24 July 2023
Delandistrogen moxeparvovec, also known as SRP-9001, trade name ELEVIDYS, is a kind of Adeno-associated virus gene therapy targeting micro dystrophin.
Read →
An Overview of Sumitomo Dainippon's 304 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
4 min read
An Overview of Sumitomo Dainippon's 304 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
24 July 2023
Sumitomo Pharma Co., Ltd. is a pharmaceutical organization based in Osaka-fu, Japan. It was founded in 1984 and has since been actively involved in the field of biomedicine.
Read →
An Overview of Grifols's 53 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
R&D Pipeline
3 min read
An Overview of Grifols's 53 Drug Pipelines ——Top 50 Pharmaceutical Companies R&D Progress
24 July 2023
Grifols SA is a pharmaceutical organization based in Spain that was founded in 1940. The company has a diverse portfolio of drugs targeting various therapeutic areas.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.